How to: share and reuse data - challenges and solutions from PrIMAVeRa project
Résumé
Background: Data sharing accelerates scientific progress and improves evidence quality. Even though journals and funding institutions require investigators to share data, only a small part of studies made their data publicly available upon publication. The procedures necessary to share retrospective data for reuse in secondary data analysis projects can be cumbersome. Objectives: Predicting the Impact of Monoclonal Antibodies & Vaccines on Antimicrobial Resistance is a European research project that aims to develop mathematical models and an epidemiological repository to assess the impact of vaccines and monoclonal antibodies on antimicrobial resistance (AMR). To accomplish the project aim, Work Package 3 was responsible for gathering historical anonymized indi- vidual patient datasets. Sources: Through a systematic search we have identified 108 eligible studies for data sharing; of which eight have completed all legal requirements and shared their datasets, with data from four infectious syndromes and seven resistant pathogens. The AMR data gathered in Predicting the Impact of Mono- clonal Antibodies & Vaccines on Antimicrobial Resistance project are publicly available in European Clinical Research Alliance on Infectious Disease epidemiology network platform (https://epi-net.eu/ primavera/about/anonymized-individual-patient-data/).
| Origine | Publication financée par une institution |
|---|---|
| Licence |